The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29.

Nucleoside transport in humans is mediated by members of two unrelated protein families, the SLC28 family of cation-linked concentrative nucleoside transporters (CNTs) and the SLC29 family of energy-independent, equilibrative nucleoside transporters (ENTs). These families contain three and four members, respectively, which differ both in the stoichiometry of cation coupling and in permeant selectivity. Together, they play key roles in nucleoside and nucleobase uptake for salvage pathways of nucleotide synthesis. Moreover, they facilitate cellular uptake of several nucleoside and nucleobase drugs used in cancer chemotherapy and treatment of viral infections. Thus, the transporter content of target cells can represent a key determinant of the response to treatment. In addition, by regulating the concentration of adenosine available to cell surface receptors, nucleoside transporters modulate many physiological processes ranging from neurotransmission to cardiovascular activity. This review describes the molecular and functional properties of the two transporter families, with a particular focus on their physiological roles in humans and relevance to disease treatment.

[1]  D. Tyrrell,et al.  Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine , 1997, Antimicrobial agents and chemotherapy.

[2]  M. Pastor-Anglada,et al.  A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter‐3 (hCNT3) protein localized in the endoplasmic reticulum , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Stephen A Baldwin,et al.  Nucleoside transporters: from scavengers to novel therapeutic targets. , 2006, Trends in pharmacological sciences.

[4]  S. Yao,et al.  An ancient prevertebrate Na+-nucleoside cotransporter (hfCNT) from the Pacific hagfish (Eptatretus stouti). , 2002, American journal of physiology. Cell physiology.

[5]  Carol E. Cass,et al.  Nucleobase Transport by Human Equilibrative Nucleoside Transporter 1 (hENT1)* , 2011, The Journal of Biological Chemistry.

[6]  C. Endres,et al.  Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[7]  Conrad C. Huang,et al.  FUNCTIONAL CHARACTERIZATION AND HAPLOTYPE ANALYSIS OF POLYMORPHISMS IN THE HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER, ENT2 , 2006, Drug Metabolism and Disposition.

[8]  R. Hevner,et al.  Expression and immunolocalization of the plasma membrane monoamine transporter in the brain , 2007, Neuroscience.

[9]  R. Messing,et al.  The type 1 equilibrative nucleoside transporter regulates anxiety‐like behavior in mice , 2007, Genes, brain, and behavior.

[10]  Conrad C. Huang,et al.  Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. , 2003, Pharmacogenetics.

[11]  S. Yao,et al.  Nucleoside transporter gene expression in wild-type and mENT1 knockout mice. , 2011, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[12]  C. Cass,et al.  Uridine Binding and Transportability Determinants of Human Concentrative Nucleoside Transporters , 2005, Molecular Pharmacology.

[13]  T. Miyawaki,et al.  Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males. , 2011, Drug metabolism and pharmacokinetics.

[14]  R. Hyde,et al.  Molecular Identification and Characterization of Novel Human and Mouse Concentrative Na+-Nucleoside Cotransporter Proteins (hCNT3 and mCNT3) Broadly Selective for Purine and Pyrimidine Nucleosides (System cib)* , 2001, The Journal of Biological Chemistry.

[15]  Carol E. Cass,et al.  Functional Characterization of Novel Human and Mouse Equilibrative Nucleoside Transporters (hENT3 and mENT3) Located in Intracellular Membranes* , 2005, Journal of Biological Chemistry.

[16]  D. Seshasayee,et al.  Equilibrative Nucleoside Transporter 3 Deficiency Perturbs Lysosome Function and Macrophage Homeostasis , 2012, Science.

[17]  S. Yao,et al.  Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). , 1997, The American journal of physiology.

[18]  C. Cass,et al.  Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1. , 2011, Biochemical pharmacology.

[19]  P. Janak,et al.  Altered glutamatergic neurotransmission in the striatum regulates ethanol sensitivity and intake in mice lacking ENT1 , 2010, Behavioural Brain Research.

[20]  E. Lee,et al.  Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. , 2007, Pharmacogenetics and genomics.

[21]  J. Mackey,et al.  Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney. , 2007, American journal of physiology. Renal physiology.

[22]  S. Yao,et al.  The Broadly Selective Human Na+/Nucleoside Cotransporter (hCNT3) Exhibits Novel Cation-coupled Nucleoside Transport Characteristics* , 2005, Journal of Biological Chemistry.

[23]  C. Cass,et al.  Improved syntheses of 5'-S-(2-aminoethyl)-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAENTA), analogues, and fluorescent probe conjugates: analysis of cell-surface human equilibrative nucleoside transporter 1 (hENT1) levels for prediction of the antitumor efficacy of gemcitabine. , 2010, Journal of medicinal chemistry.

[24]  J. Mackey,et al.  Chapter 9 Molecular mechanisms of nucleoside and nucleoside drug transport , 2000 .

[25]  J. Buolamwini,et al.  Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity. , 2010, Biochemical pharmacology.

[26]  J. Mackey,et al.  The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. , 2002, Cancer treatment and research.

[27]  S. Yao,et al.  Molecular biology of nucleoside transporters and their distributions and functions in the brain. , 2011, Current topics in medicinal chemistry.

[28]  G. Peters,et al.  Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. , 2004, Biochemical pharmacology.

[29]  K. Giacomini,et al.  Molecular Determinants of Substrate Selectivity in Na+-dependent Nucleoside Transporters* , 1997, The Journal of Biological Chemistry.

[30]  Seok-Yong Lee,et al.  Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 Å , 2012, Nature.

[31]  Conrad C. Huang,et al.  Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2 , 2005, Pharmacogenetics and genomics.

[32]  N. Kannan,et al.  Human Equilibrative Nucleoside Transporter-3 (hENT3) Spectrum Disorder Mutations Impair Nucleoside Transport, Protein Localization, and Stability* , 2010, The Journal of Biological Chemistry.

[33]  C. Cass,et al.  Cation coupling properties of human concentrative nucleoside transporters hCNT1, hCNT2 and hCNT3 , 2007, Molecular membrane biology.

[34]  Stephen A Baldwin,et al.  Transepithelial fluxes of adenosine and 2'-deoxyadenosine across human renal proximal tubule cells: roles of nucleoside transporters hENT1, hENT2, and hCNT3. , 2009, American journal of physiology. Renal physiology.

[35]  Min Huang,et al.  Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun N-terminal kinase. , 2011, Biochemical and biophysical research communications.

[36]  M. Hayden,et al.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Paterson,et al.  Enantiomeric selectivity of adenosine transport systems in mouse erythrocytes and L1210 cells. , 1989, The Biochemical journal.

[38]  C. Endres,et al.  The Role of Nucleoside Transporters in the Erythrocyte Disposition and Oral Absorption of Ribavirin in the Wild-Type and Equilibrative Nucleoside Transporter 1(−/−) Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.

[39]  C. Tse,et al.  Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[40]  S. Yao,et al.  Influence of Sugar Ring Conformation on the Transportability of Nucleosides by Human Nucleoside Transporters , 2011, Chembiochem : a European journal of chemical biology.

[41]  Yurong Lai,et al.  Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs* , 2004, Journal of Biological Chemistry.

[42]  Conrad C. Huang,et al.  Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. , 2004, Molecular pharmacology.

[43]  S. Yao,et al.  Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[44]  A. Bonci,et al.  The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference , 2004, Nature Neuroscience.

[45]  L. Desouza,et al.  The Equilibrative Nucleoside Transporter (ENT1) can be phosphorylated at multiple sites by PKC and PKA , 2011, Molecular membrane biology.

[46]  S. Yao,et al.  Electrophysiological characterization of a recombinant human Na+‐coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes , 2004, The Journal of physiology.

[47]  G. Peters,et al.  The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues , 2010, Nucleosides, nucleotides & nucleic acids.

[48]  M. Pastor-Anglada,et al.  SLC28 genes and concentrative nucleoside transporter (CNT) proteins , 2008 .

[49]  E. Burchard,et al.  Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3) , 2005, The Pharmacogenomics Journal.

[50]  C. Cass,et al.  Coupling of CFTR-mediated anion secretion to nucleoside transporters and adenosine homeostasis in calu-3 cells , 2003, The Journal of Membrane Biology.

[51]  John R Mackey,et al.  Human Nucleoside Transporters: Biomarkers for Response to Nucleoside Drugs , 2009, Nucleosides, nucleotides & nucleic acids.

[52]  M. Pastor-Anglada,et al.  SLC28 genes and concentrative nucleoside transporter (CNT) proteins. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[53]  J. Buolamwini,et al.  CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). , 2009, Bioorganic & medicinal chemistry letters.

[54]  C. Cass,et al.  The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs , 2007, Cancer and Metastasis Reviews.

[55]  J. Buolamwini,et al.  Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. , 2008, Bioorganic & medicinal chemistry.

[56]  Donghui Li,et al.  Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer , 2010, Cancer.

[57]  M. Pastor-Anglada,et al.  The Human Concentrative Nucleoside Transporter-3 C602R Variant Shows Impaired Sorting to Lipid Rafts and Altered Specificity for Nucleoside-Derived Drugs , 2010, Molecular Pharmacology.

[58]  G. Peters,et al.  Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models , 2010, Investigational New Drugs.

[59]  M. Wuest,et al.  Biodistribution and Uptake of 3′-Deoxy-3′-Fluorothymidine in ENT1-Knockout Mice and in an ENT1-Knockdown Tumor Model , 2010, The Journal of Nuclear Medicine.

[60]  I. Coe,et al.  Disrupted plasma membrane localization and loss of function reveal regions of human equilibrative nucleoside transporter 1 involved in structural integrity and activity. , 2009, Biochimica et biophysica acta.

[61]  I. Coe,et al.  Characterization and Functional Analysis of the Promoter for the Human Equilibrative Nucleoside Transporter Gene, hENT1 , 2007, Nucleosides, nucleotides & nucleic acids.

[62]  C. Cass,et al.  Demonstration of Equilibrative Nucleoside Transporters (hENT1 and hENT2) in Nuclear Envelopes of Cultured Human Choriocarcinoma (BeWo) Cells by Functional Reconstitution in Proteoliposomes* , 1998, The Journal of Biological Chemistry.

[63]  C. K. Chu,et al.  L-Nucleosides as chemotherapeutic agents. , 2001, FEMS microbiology letters.

[64]  J. Kamps,et al.  Biodistribution and uptake of liposomes in vivo. , 2004, Methods in enzymology.

[65]  Donghui Li,et al.  Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity , 2009, Clinical Cancer Research.

[66]  Victoria J. McIntosh,et al.  Adenosine Receptor-Mediated Cardioprotection , 2012, Journal of cardiovascular pharmacology and therapeutics.

[67]  J. Hayashi,et al.  In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[68]  J. Rüschoff,et al.  Expression of the High-Affinity Fluoropyrimidine-Preferring Nucleoside Transporter hCNT1 Correlates with Decreased Disease-Free Survival in Breast Cancer , 2006, Oncology.

[69]  A. Paterson,et al.  Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport , 2000, Leukemia.

[70]  W. Gerald,et al.  Adenosine Transporter ENT4 Is a Direct Target of EWS/WT1 Translocation Product and Is Highly Expressed in Desmoplastic Small Round Cell Tumor , 2008, PloS one.

[71]  Joanne Wang,et al.  Adenosine Transport by Plasma Membrane Monoamine Transporter: Reinvestigation and Comparison with Organic Cations , 2010, Drug Metabolism and Disposition.

[72]  M. Pastor-Anglada,et al.  Functional analysis of the human concentrative nucleoside transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket. , 2012, American journal of physiology. Cell physiology.

[73]  Sebastian Radestock,et al.  The alternating-access mechanism of MFS transporters arises from inverted-topology repeats. , 2011, Journal of molecular biology.

[74]  S. Colgan,et al.  HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia , 2005, The Journal of experimental medicine.

[75]  S. Yao,et al.  The equilibrative nucleoside transporter family, SLC29 , 2004, Pflügers Archiv.

[76]  C. Cass,et al.  Renal nucleoside transporters: physiological and clinical implications. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[77]  Nora Hammack,et al.  Type 1 Equilibrative Nucleoside Transporter Regulates Ethanol Drinking Through Accumbal N-Methyl-D-Aspartate Receptor Signaling , 2011, Biological Psychiatry.

[78]  John R. Mackey,et al.  The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma , 2004, Clinical Cancer Research.

[79]  C. Cass,et al.  Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. , 2008, Leukemia research.

[80]  M. P. Gallagher,et al.  Subcellular Distribution and Membrane Topology of the Mammalian Concentrative Na+-Nucleoside Cotransporter rCNT1* , 2001, The Journal of Biological Chemistry.

[81]  Adam P Dicker,et al.  Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. , 2009, Gastroenterology.

[82]  S. Yao,et al.  The Role of Human Nucleoside Transporters in Uptake of 3′-Deoxy-3′-fluorothymidine , 2008, Molecular Pharmacology.

[83]  C. Cass,et al.  Distribution and Functional Characterization of Equilibrative Nucleoside Transporter-4, a Novel Cardiac Adenosine Transporter Activated at Acidic pH , 2006, Circulation research.

[84]  S. Yao,et al.  Identification of Amino Acid Residues Responsible for the Pyrimidine and Purine Nucleoside Specificities of Human Concentrative Na+ Nucleoside Cotransporters hCNT1 and hCNT2* , 1999, The Journal of Biological Chemistry.

[85]  L. Mangravite,et al.  Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. , 2003, European journal of pharmacology.

[86]  M. Eguchi,et al.  Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection. , 2010, American journal of physiology. Heart and circulatory physiology.

[87]  S. Yao,et al.  A Conformationally Mobile Cysteine Residue (Cys-561) Modulates Na+ and H+ Activation of Human CNT3* , 2008, Journal of Biological Chemistry.

[88]  John R. Mackey,et al.  Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma , 2009, Clinical Cancer Research.

[89]  C. Cass,et al.  Uridine recognition motifs of human equilibrative nucleoside transporters 1 and 2 produced in Saccharomyces cerevisiae. , 2004 .

[90]  J. Mackey,et al.  Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. , 1998, Molecular membrane biology.

[91]  S. Yao,et al.  Equilibrative Nucleoside Transport Proteins , 2003 .

[92]  P. Casanello,et al.  Human equilibrative nucleoside transporters 1 and 2 may be differentially modulated by A2B adenosine receptors in placenta microvascular endothelial cells from pre-eclampsia. , 2008, Placenta.

[93]  C. Cass,et al.  Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures , 2008, Cancer Chemotherapy and Pharmacology.